Phathom Pharmaceuticals, Inc. (PHAT) — Stock Score Summary

Phathom Pharmaceuticals, Inc. (PHAT) has a MoatMap StockRank of 31/100 based on Quality (33/100), Value (50/100), and Momentum (36/100) factor scores. The current signal is SELL. Phathom Pharmaceuticals is a commercial-stage biopharma company focused on gastrointestinal therapies. It is a single-product story dependent on the commercial ramp of Voquezna, lacking the diversified moat or CDMO platform dynamics we seek.

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases. Its lead product, Voquenza (vonoprazan), is a potassium-competitive acid blocker approved for certain acid-related disorders. The company's competitive position is driven by its differentiated therapeutic offerings and its strategic focus on the significant market for GI disorders.

Key Financial Metrics

Price$9.82
Market Cap$823M
P/E (Forward)6.85
Price/Book-2.32
Return on Invested Capital-120.5%
Gross Margin84.9%
Operating Margin-26.5%
Revenue Growth104.4%
Free Cash Flow$-78M

Phathom Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Phathom Pharmaceuticals, Inc.’s (PHAT) StockRank?
MoatMap’s StockRank for Phathom Pharmaceuticals, Inc. (PHAT) is 31/100, with a Sell signal. It is a composite of Quality (33), Value (50), and Momentum (36) factor ranks across MoatMap’s 19,000+ stock universe.
Does Phathom Pharmaceuticals, Inc. have an economic moat?
Phathom Pharmaceuticals, Inc. (PHAT) has a Quality factor score of 33/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Phathom Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Phathom Pharmaceuticals, Inc. (PHAT) is Sell, based on a StockRank of 31/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Phathom Pharmaceuticals, Inc. in?
Phathom Pharmaceuticals, Inc. (PHAT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksPHAT deep dive reportAI ChampionsHow we score stocksSense-check another stock